Balancing efficacy and financial toxicity in the management of metastatic castration-sensitive prostate cancer

被引：0
作者：
Sridhar, Srikala S. [1 ]
机构：
[1] Princess Margaret Canc Ctr, Toronto, ON, Canada
来源：
CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL | 2019年 / 13卷 / 12期
关键词：
THERAPY;
D O I：
10.5489/cuaj.6346
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：404 / 405
页数：2
相关论文
共 50 条
  • [1] Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
    Chi, Kim N.
    Agarwal, Neeraj
    Bjartell, Anders
    Chung, Byung Ha
    Pereira de Santana Gomes, Andrea J.
    Given, Robert
    Juarez Soto, Alvaro
    Merseburger, Axel S.
    Ozguroglu, Mustafa
    Uemura, Hirotsugu
    Ye, Dingwei
    Deprince, Kris
    Naini, Vahid
    Li, Jinhui
    Cheng, Shinta
    Yu, Margaret K.
    Zhang, Ke
    Larsen, Julie S.
    McCarthy, Sharon
    Chowdhury, Simon
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (01) : 13 - 24
  • [2] The evolving options in metastatic castration-sensitive prostate cancer
    Hamilou, Zineb
    CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE, 2020, 14 (03) : 270 - 275
  • [3] Abiraterone or Docetaxel for Castration-sensitive Metastatic Prostate Cancer? That Is the Question!
    Messina, Carlo
    Messina, Marco
    Boccardo, Francesco
    EUROPEAN UROLOGY, 2018, 73 (01) : 147 - 148
  • [4] The addition of apalutamide to ADT in the treatment of metastatic castration-sensitive prostate cancer: safety and efficacy
    Barata, Pedro
    Swami, Umang
    Agarwal, Neeraj
    EXPERT REVIEW OF ANTICANCER THERAPY, 2020, 20 (03) : 147 - 150
  • [5] A TITAN step forward: apalutamide for metastatic castration-sensitive prostate cancer
    Kwon, Daniel Hyuck-Min
    Friedlander, Terence
    ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7
  • [6] Prognostic Significance of Time to Castration Resistance in Patients With Metastatic Castration-sensitive Prostate Cancer
    Miyake, Hideaki
    Matsushita, Yuto
    Watanabe, Hiromitsu
    Tamura, Keita
    Motoyama, Daisuke
    Ito, Toshiki
    Sugiyama, Takayuki
    Otsuka, Atsushi
    ANTICANCER RESEARCH, 2019, 39 (03) : 1391 - 1396
  • [7] Commentary on: Abiraterone Plus Prednisolone in Metastatic, Castration-sensitive Prostate Cancer
    Struss, Werner J.
    Black, Peter C.
    UROLOGY, 2017, 109 : 1 - 2
  • [8] Transcriptomic and clinical heterogeneity of metastatic disease timing within metastatic castration-sensitive prostate cancer
    Sutera, P. A.
    Shetty, A. C.
    Hakansson, A.
    Van der Eecken, K.
    Song, Y.
    Liu, Y.
    Chang, J.
    Fonteyne, V.
    Mendes, A. A.
    Lumen, N.
    Delrue, L.
    Verbeke, S.
    De Man, K.
    Rana, Z.
    Hodges, T.
    Hamid, A.
    Roberts, N.
    Song, D. Y.
    Pienta, K.
    Ross, A. E.
    Feng, F.
    Joniau, S.
    Spratt, D.
    Gillessen, S.
    Attard, G.
    James, N. D.
    Lotan, T.
    Davicioni, E.
    Sweeney, C.
    Tran, P. T.
    Deek, M. P.
    Ost, P.
    ANNALS OF ONCOLOGY, 2023, 34 (07) : 605 - 614
  • [9] Phenotypes of circulating tumour cells predict time to castration resistance in metastatic castration-sensitive prostate cancer
    Yang, Yun-Jie
    Kong, Yun-Yi
    Li, Gao-Xiang
    Wang, Yue
    Ye, Ding-Wei
    Dai, Bo
    BJU INTERNATIONAL, 2019, 124 (02) : 258 - 267
  • [10] Real-world evaluation of upfront docetaxel in metastatic castration-sensitive prostate cancer
    Isaksson, Jenny
    Green, Henrik
    Papantoniou, Dimitrios
    Pettersson, Linn
    Anden, Mats
    Rosell, Johan
    Avall-Lundqvist, Elisabeth
    Elander, Nils Oskar
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2021, 12 (11): : 1009 - 1022
12345